Literature DB >> 16038047

Effect of c-fos antisense probe on prostaglandin E2-induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells.

Yong-Qi Li1, Kai-Shan Tao, Ning Ren, Yi-Hu Wang.   

Abstract

AIM: To examine the effect of prostaglandin E2 (PGE2) on the expression of vascular endothelial growth factor (VEGF) mRNA in the human hepatocellular carcinoma (HCC) HepG2 cells and the possible involvement of c-fos protein in this process.
METHODS: Human HCC HepG2 cells were divided into three groups treated respectively with PGE2, a combination of PGE2 and c-fos antisense oligodeoxynucleotide (ASO), and PGE2 plus c-fos sense oligodeoxynucleotide (SO). The expression of VEGF mRNA in HepG2 cells after different treatments was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The relative expression level of VEGF mRNA in HepG2 cells in each group was measured.
RESULTS: Administration of PGE2 resulted in an increased expression of c-fos and VEGF mRNA in HepG2 cells. The relative expression level of c-fos mRNA reached the peak at 3 h (68.4+/-4.7%) after PGE2 treatment, which was significantly higher than that at 0 h (20.6+/-1.7%, P<0.01). Whereas, the highest expression level of VEGF mRNA was observed at 6 h (100.5+/-6.1%) after PGE2 treatment, which was significantly higher than that at 0 h (33.2+/-2.4%, P<0.01). C-fos ASO significantly reduced PGE2-induced VEGF mRNA expression in HepG2 cells.
CONCLUSION: PGE2 increases the expression and secretion of VEGF in HCC cells by activating the transcription factor c-fos, promotes the angiogenesis of HCC and plays an important role in the pathogenesis of liver cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038047      PMCID: PMC4434675          DOI: 10.3748/wjg.v11.i28.4427

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope.

Authors:  M Bhattacharya; K Peri; A Ribeiro-da-Silva; G Almazan; H Shichi; X Hou; D R Varma; S Chemtob
Journal:  J Biol Chem       Date:  1999-05-28       Impact factor: 5.157

2.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

Review 3.  Cyclooxygenases and prostaglandins: shaping up the immune response.

Authors:  Bianca Rocca; Garret A FitzGerald
Journal:  Int Immunopharmacol       Date:  2002-04       Impact factor: 4.932

4.  Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2.

Authors:  Hiromichi Ito; Mark Duxbury; Eric Benoit; Thomas E Clancy; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Prostaglandins induce proliferation of rat hepatocytes through a prostaglandin E2 receptor EP3 subtype.

Authors:  N Hashimoto; T Watanabe; Y Ikeda; H Yamada; S Taniguchi; H Mitsui; K Kurokawa
Journal:  Am J Physiol       Date:  1997-03

6.  Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.

Authors:  M Casibang; S Purdom; S Jakowlew; L Neckers; F Zia; P Ben-Av; T Hla; L You; D M Jablons; T W Moody
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

Review 7.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

8.  Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma.

Authors:  Satoru Imura; Hidenori Miyake; Keisuke Izumi; Seiki Tashiro; Hisanori Uehara
Journal:  J Med Invest       Date:  2004-08

Review 9.  Prostaglandins and the regulation of tumor growth.

Authors:  David Bishop-Bailey; Sara Calatayud; Timothy D Warner; Timothy Hla; Jane A Mitchell
Journal:  J Environ Pathol Toxicol Oncol       Date:  2002       Impact factor: 3.567

10.  Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.

Authors:  Hideki Amano; Izumi Hayashi; Hirahito Endo; Hidero Kitasato; Shohei Yamashina; Takayuki Maruyama; Michiyoshi Kobayashi; Kazutoyo Satoh; Masami Narita; Yukihiko Sugimoto; Takahiko Murata; Hirokuni Yoshimura; Shuh Narumiya; Masataka Majima
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

View more
  5 in total

1.  Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events.

Authors:  Konstantina Katsarou; Alexandros Alpha Lavdas; Panagiota Tsitoura; Elisavet Serti; Panagiotis Markoulatos; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

2.  Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase.

Authors:  Elisavet Serti; Polyxeni P Doumba; George Thyphronitis; Panagiota Tsitoura; Konstantina Katsarou; Pelagia Foka; Manousos M Konstandoulakis; John Koskinas; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

3.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

4.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

5.  c-FOS suppresses ovarian cancer progression by changing adhesion.

Authors:  L Oliveira-Ferrer; K Rößler; V Haustein; C Schröder; D Wicklein; D Maltseva; N Khaustova; T Samatov; A Tonevitsky; S Mahner; F Jänicke; U Schumacher; K Milde-Langosch
Journal:  Br J Cancer       Date:  2013-12-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.